Full-Time

Safety Sciences Assistant Manager

Updated on 8/18/2026

Deadline 8/25/26
Fortrea

Fortrea

10,001+ employees

Global CRO providing Phase I-IV trials

No salary listed

Pune, Maharashtra, India

In Person

Travel of up to 10% is required, including occasional overnight stays.

Category
Medical, Clinical & Veterinary (1)
Required Skills
Microsoft Office
Microsoft Windows
Quality Assurance (QA)

Get referred to Fortrea

See people who can refer or advise you

Requirements
  • Actual experience processing adverse event and serious adverse event reports, generating patient narratives and queries, working within safety databases, and supporting regulatory submissions.
  • Relevant experience in the pharmaceutical, biotechnology, or contract research organization industry, or in Medical Affairs, Clinical Data Entry and Clinical Data Management, Clinical Data Monitoring, Regulatory Affairs, or Quality Assurance.
  • Good verbal, written, and presentation skills.
  • Ability to interact with and influence line and middle management, staff, and external contacts at a functional and tactical level.
  • High degree of accuracy and attention to detail.
  • Knowledge of medical and drug terminology.
  • Knowledge of Good Clinical Practice related to clinical safety documentation.
  • Knowledge of International Council for Harmonisation guidelines.
  • Knowledge of worldwide regulatory requirements and adverse event reporting for marketed and investigational products.
  • Knowledge and understanding of industry and research and development processes and objectives.
  • Ability to work independently with minimal supervision.
  • Good keyboard skills; knowledge of Microsoft Office and Windows is beneficial.
  • Ability to anticipate and identify problems and take appropriate corrective action.
Responsibilities
  • Manage the receipt and processing of adverse event reports from spontaneous sources and clinical trials, including safety database entry, adverse event review, patient narratives with coding, follow-up of missing information, and listedness assessment against the appropriate label.
  • Manage submission of expedited serious adverse event reports to clients, regulatory authorities, ethics committees, investigators, third-party vendors, partners, and project personnel within specified timelines.
  • Prioritize cases requiring expedited reporting and submit them within applicable regulatory and study-specific timelines.
  • Prepare pharmacovigilance reports, including Individual Case Summary Reports of Serious Adverse Events, Annual Investigational New Drug reports, European Annual Safety Reports, Development Safety Update Reports, periodic report line listings, and aggregate reports.
  • Perform routine quality reviews of adverse event and aggregate reports to ensure case processing and data quality meet global regulatory compliance requirements, including audit support.
  • Maintain understanding of company and client-specific safety database conventions.
  • Participate in signal detection and trend and pattern recognition activities.
  • Lead or participate in projects that improve team or division performance, including serving as a lead contact for global projects and supporting communication and process harmonization.
  • Work with Data Management or clients on reconciliation of safety databases.
  • Monitor workflow for assigned studies and programs to ensure deadlines are met.
  • Prepare and deliver safety presentations for investigator meetings, client capability meetings, and internal department overviews.
  • Maintain understanding of standard operating procedures, work instructions, guidance documents, and directives related to safety management, reporting, and pharmacovigilance.
  • Contribute to the development of departmental work instructions and standard operating procedures.
  • Generate monthly status and project-specific reports while ensuring the quality and accuracy of metrics and data.
  • Support and train less experienced safety staff in case handling and adverse event reporting, and contribute to training material development and updates.
  • Contribute to Safety Management Plans, Reconciliation Plans, and other safety-specific plans under supervision.
  • Make adverse event reporting decisions within the guidelines of each project.
  • Assist management in identifying out-of-scope work.
  • Participate in project team and client meetings and liaise with clients where appropriate.
  • Participate in client or regulatory audits and support audit preparation.
  • Support quality issue resolution and process improvement initiatives.
  • Assist in reviewing cumulative safety data for submission to Drug Safety Monitoring Boards, regulatory authorities, or clients.
  • Assist with setting up and providing data to Safety Committees and Drug Safety Monitoring Boards, and assist in coordinating endpoint committees.
  • Build and maintain relationships across pharmacovigilance and safety functional units.
  • Travel up to 10% of the time, including overnight stays as necessary.
  • Perform other assigned duties.
Desired Qualifications
  • Knowledge of medical device reporting.
  • Knowledge of Microsoft Office and Windows.
  • Experience with medical device reporting.

Fortrea is a global contract research organization that provides clinical development services for the life sciences industry. It offers full service, functional service, and hybrid outsourcing models across Phase I–IV trials, clinical pharmacology, and consulting, serving biotech, biopharma, medical devices, and diagnostics. Its work is delivered through a network of investigators and specialized teams in approximately 100 countries, supporting trial design, execution, data management, and regulatory compliance. Fortrea’s approach combines its legacy experience from Covance and Labcorp with a pureplay CRO model to deliver fit-for-purpose solutions and agile project delivery. This positions it to manage trials across more than 20 therapeutic areas with scientific rigor and operational excellence. The company aims to bring predictability to clinical trial execution and help clients turn research ideas into real-world outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

Durham, North Carolina

Founded

2023

Get referred to Fortrea

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Fortrea raised 2026 revenue guidance to $2.62 billion-$2.69 billion on July 29, 2026.
  • Book-to-bill stayed above 1.0x for four straight quarters, supporting backlog conversion.
  • Q2 2026 operating margin improved to 2.2%, showing cost cuts and discipline are working.

What critics are saying

  • Jason Knoblauch is on paid leave after Delaware Chancery restraints; finance leadership remains unstable.
  • Q2 2026 revenue still fell 4.5%, signaling weak demand and pricing pressure.
  • Large-pharma FSP renewals already forced pricing concessions; another renewal cycle can crush 2027 margins.

What makes Fortrea unique

  • Fortrea’s April 7, 2026 FIT platform embeds AI into clinical trial operations.
  • Fortrea spans phase I-IV trials across roughly 100 countries with deep investigator-site reach.
  • Fortrea’s 2023 Labcorp spinout preserved a focused CRO model for pharma, biotech, and devices.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Unlimited Paid Time Off

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

27%

1 year growth

27%

2 year growth

27%
Yahoo Finance
Aug 15th, 2026
Fortrea shares fall 5.7% despite Q2 revenue beat of $678M in drug development sector review

Fortrea, a contract research organisation spun off from Labcorp in 2023, reported Q2 revenues of $678.2 million, down 4.5% year-on-year but exceeding analyst expectations by 4.7%. The company helps pharmaceutical, biotech, and medical device companies develop products through clinical trials and support services. Chief executive officer Anshul Thakral said the results reflected continued progress against the company's strategy and disciplined execution. The quarter saw Fortrea beat earnings per share estimates, with full-year revenue guidance surpassing analyst expectations. Among the eight drug development inputs and services stocks tracked, revenues collectively beat consensus estimates by 4.1%. Despite posting the slowest revenue growth in the group, the sector's share prices rose 12.6% on average. Fortrea's stock fell 5.7% following the results and currently trades at $19.52.

Yahoo Finance
Jul 29th, 2026
Fortrea beats Q2 revenue estimates despite 4.5% decline, raises full-year guidance to $2.66B

Fortrea Holdings reported second-quarter revenue of $678.2 million, exceeding analyst estimates by 4.7% despite a 4.5% year-on-year decline. The clinical research company's adjusted earnings per share of $0.23 beat consensus estimates by 27.2%. The company raised its full-year revenue guidance to $2.66 billion at the midpoint, up 2.1% from previous guidance and 1.8% above analyst expectations. Full-year EBITDA guidance of $212.5 million also surpassed estimates. Operating margin improved significantly to 2.2%, compared to negative 46.5% in the same quarter last year. CEO Anshul Thakral said the results reflect continued progress against the company's strategy. However, analysts project revenue to remain flat over the next 12 months, suggesting limited near-term growth prospects.

Yahoo Finance
Jun 26th, 2026
Fortrea appoints Jason Knoblauch as CFO, reiterates $2.55B-$2.65B revenue guidance

Fortrea, a global contract research organisation, has appointed Jason Knoblauch as chief financial officer, effective 6 July 2026. He will succeed Jill McConnell, who is stepping down after helping establish Fortrea as an independent CRO. Knoblauch joins from Clario, where he served as CFO. He previously held the CFO position at Curia and various financial leadership roles at Pharmaceutical Product Development, including interim CFO and helping lead the company to a successful IPO in 2020. Earlier, he worked in PricewaterhouseCoopers' Transaction Services practice. The company reiterated its 2026 financial guidance, targeting revenues between $2,550 million and $2,650 million, with adjusted EBITDA of $190 million to $220 million.

Stock Story, Inc
Jun 24th, 2026
Why Fortrea (FTRE) stock is trading up today.

Why Fortrea (FTRE) stock is trading up today. Anthony lee /. June 24, 2026 What happened? Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE) jumped 4.6% in the morning session after Barclays raised its price target on the company's shares to $18 from $16, while maintaining an Equal Weight rating. The adjustment by analyst Luke Sergott was part of a second-quarter preview for the life science and diagnostic tools space. According to the analyst's research note, tools are "gaining favor among healthcare subsectors," a trend that is likely to continue into the earnings reporting season. Barclays expects companies in the sector to report quarterly results that are in-line with or slightly better than expectations. What is the market telling us. Fortrea's shares are extremely volatile and have had 64 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The biggest move we wrote about over the last year was 8 months ago when the stock gained 25.3% on the news that the company reported third-quarter financial results that showed stronger-than-expected revenue and an improved outlook for the full year. For the third quarter, Fortrea announced revenues of $701.3 million, which surpassed analyst estimates. However, its adjusted earnings of $0.12 per share fell short of projections. Despite the mixed bottom-line results, investors appeared to focus on the company's future prospects. Fortrea raised its revenue guidance for the full year to a midpoint of $2.73 billion, up from its previous forecast of $2.65 billion. This improved outlook, along with the strong quarterly sales, signaled confidence in the company's growth, outweighing the earnings miss. Fortrea is up 2.9% since the beginning of the year, and at $17.30 per share, it is trading close to its 52-week high of $18.40 from January 2026. Investors who bought $1,000 worth of Fortrea's shares at the IPO in June 2023 would now be looking at an investment worth $574.58. WHILE YOU'RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You've probably never heard of it. This is what the early days of Palantir looked like before it became a $437 billion giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.

Yahoo Finance
May 15th, 2026
Fortrea beats Q1 estimates with $636.5M revenue as biotech rebound lifts margins

Fortrea exceeded Wall Street expectations in its first quarter results, posting revenue of $636.5 million versus estimates of $627.5 million and adjusted earnings per share of $0.16 against estimates of $0.05. The clinical research services company's adjusted EBITDA reached $47 million, beating analyst estimates of $34.61 million. CEO Anshul Thakral attributed the performance to improved commercial execution and a rebound in biotech client activity, with the company achieving a higher book-to-bill ratio for the third consecutive quarter. CFO Jill McConnell highlighted operational discipline and cost-optimisation initiatives as key drivers of margin expansion. Fortrea reaffirmed its full-year revenue guidance of $2.6 billion at the midpoint and raised EBITDA guidance to $205 million, above analyst estimates of $201.8 million. The company's market capitalisation stands at $1.42 billion.